Akari is biopharmaceutical company advancing the clinical development of Coversin, a complement inhibitor derived from the saliva of a species of tick. Coversin shares a mechanism of action with the $2.59bn drug Soliris (Alexion, 2015 sales), and the company will be seeking approval for the same ultra-rare autoimmune hemolytic disorders as Soliris, as well as two other immune disorders without current treatments. The drug is currently in a dose ranging study and has successfully stabilized a
20 Jun 2016
Set up to compete in the Soliris market and more
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Set up to compete in the Soliris market and more
- Published:
20 Jun 2016 -
Author:
Maxim Jacobs -
Pages:
16
Akari is biopharmaceutical company advancing the clinical development of Coversin, a complement inhibitor derived from the saliva of a species of tick. Coversin shares a mechanism of action with the $2.59bn drug Soliris (Alexion, 2015 sales), and the company will be seeking approval for the same ultra-rare autoimmune hemolytic disorders as Soliris, as well as two other immune disorders without current treatments. The drug is currently in a dose ranging study and has successfully stabilized a